Abstract 381P
Background
Oral squamous cell carcinoma (OSCC) is highly prevalent in South-East Asia including Indonesia. Recurrence and early mortality in OSCC patients cause significant health burden. Subclassification of patients with high risks of locoregional recurrence and early death is beneficial for planning of treatment intensification and surveillance.
Methods
Formalin-fixed paraffin embedded (FFPE) tissues of OSCC were immuno-stained and analyzed for p16 expression. Semi-quantitative German scoring system for p16 was used. Risk factors and clinical parameters of OSCC patients were collected and compared to identify factors associated with recurrences and overall survival.
Results
OSCC recurrences and mortality were observed in in 82% and 78% patients (N=60) after a median follow-up of 32 months. Larger tumor size (T3 and T4) was significantly associated with both recurrences and mortality (OR = 3.967,95% CI = 1.007-15.618 and OR = 5.885, 95% CI = 1.541-22.47, respectively). Positive p16 staining was observed in 31% of tumors. Patients with p16 -positive expression were significantly associated with longer recurrence-free and overall survivals (medians of recurrence-free survivals were 31.2 vs 19.0 months, P=0.038 and overall survivals were 39.0 vs 28.8 months, P=0.048; respectively). Other clinical variables including early stages, negative cervical nodes, non-keratinizing tumors, and negative surgical margin status were significantly associated with longer recurrence-free and survivals (log-rank tests, P<0.05).
Conclusions
P16 -positive staining, early stages, positive cervical lymph node infiltration, and positive surgical margins are associated with better prognosis in OSCC patients. The study emphasizes the importance of early detection and the potential use of p16 and other clinical markers as prognostic markers in OSCC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
S. L. Anwar.
Funding
Universitas Gadjah Mada.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
397P - Comparison between Y-site co-infusion versus standard dexamethasone for preventing hypersensitivity reactions from oxaliplatin administration: A randomized controlled trial
Presenter: jarearnjit Phavirunsiri
Session: Poster Display
Resources:
Abstract
398P - Evaluation of the effectiveness of denosumab therapy giant cell tumor of the pelvis
Presenter: Abbos Nurjabov
Session: Poster Display
Resources:
Abstract
399P - Long-term outcomes of patients with gastric cancer who received the best supportive care without any anticancer treatment
Presenter: Yohei Arihara
Session: Poster Display
Resources:
Abstract
401TiP - Oral opioid vs intravenous patient-controlled analgesia (PCA) with hydromorphone bolus-only or continuous infusion to maintain analgesia for severe cancer pain: A randomized phase III trial
Presenter: Cheng Huang
Session: Poster Display
Resources:
Abstract
407P - K-TrackTM: A streamlined personalized assay to detect molecular residual disease in solid tumors
Presenter: Nam Vo
Session: Poster Display
Resources:
Abstract
408P - Increased EGFR and MET expression and corresponding tumor microenvironment (TME) change in hepatocellular carcinoma (HCC) tissues after sorafenib (Sora) treatment
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
410P - Systematic evaluation of cell-free DNA fragmentation patterns for cancer diagnosis and enhanced cancer detection through integration of multiple fragmentations
Presenter: Xiangy-Yu Meng
Session: Poster Display
Resources:
Abstract
412P - Multiplex digital spatial profiling (DSP) of protein reveals distinct immune and molecular phenotypes in hepatocellular carcinoma
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
413P - Clinical utility of advanced features provided by circulating tumor DNA-based comprehensive genomic profiling
Presenter: Young-gon Kim
Session: Poster Display
Resources:
Abstract
414P - Landscape of ERBB2 mutations in advanced cancers (AC) using circulating tumor DNA (ctDNA) next-generation sequencing (NGS) in Asia and Middle East (AME)
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract